Developing oral calcitonin for the treatment and prevention of osteoporosis

Tarsa Therapeutics is developing OSTORA, an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis. Calcitonin has a long history of safety and efficacy as an osteoporosis therapy but currently is only available in injectable and intranasal formulations. Tarsa’s oral calcitonin tablet has the potential to provide calcitonin’s proven safety and efficacy with the major advantage of once-daily oral dosing. Tarsa’s Phase III clinical trial—the ORACAL study—assessing OSTORA as a treatment for postmenopausal osteoporosis, yielded positive safety and efficacy results. Tarsa is currently preparing to file an NDA with the U.S. Food & Drug Administration for OSTORA as a treatment for post-menopausal osteoporosis. Learn more

The Osteoporosis Challenge

doc-reading-xrayOsteoporosis is a common but silent disease characterized  by the loss of bone mass that leads to bone fragility and  heightened risk of fractures.   Osteoporosis affects an estimated 75 million people in the US, Europe and Japan and is an important cause of  disability and loss of independence worldwide. Learn more